Coherus BioSciences Inc (CHRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Coherus BioSciences Inc (CHRS) has a cash flow conversion efficiency ratio of -0.323x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.72 Million) by net assets ($61.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Coherus BioSciences Inc net asset quality index to measure how much of total assets are equity-financed.
Coherus BioSciences Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Coherus BioSciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CHRS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Coherus BioSciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coherus BioSciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Saniona AB
ST:SANION
|
-0.125x |
|
Caisse Régionale de Crédit Agricole du Morbihan
PA:CMO
|
0.004x |
|
ST George Mining Ltd
AU:SGQ
|
-0.089x |
|
Gunung Raja Paksi
JK:GGRP
|
-0.004x |
|
Smart Parking Ltd
AU:SPZ
|
0.132x |
|
Sichuan Dowell Science and Technology Inc
SHE:300535
|
0.004x |
|
PERPETUAL EQU. INV.
F:P82
|
N/A |
|
Liaoning Kelong Fine ChemicalInc
SHE:300405
|
0.005x |
Annual Cash Flow Conversion Efficiency for Coherus BioSciences Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Coherus BioSciences Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Coherus BioSciences Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $61.01 Million | $-138.51 Million | -2.270x | -1565.96% |
| 2024-12-31 | $-131.99 Million | $-20.44 Million | 0.155x | -82.87% |
| 2023-12-31 | $-193.43 Million | $-174.88 Million | 0.904x | -48.47% |
| 2022-12-31 | $-137.42 Million | $-241.12 Million | 1.755x | +558.10% |
| 2021-12-31 | $97.73 Million | $-37.43 Million | -0.383x | -169.82% |
| 2020-12-31 | $280.97 Million | $154.15 Million | 0.549x | +103.57% |
| 2019-12-31 | $105.21 Million | $28.36 Million | 0.269x | -93.47% |
| 2018-12-31 | $-38.59 Million | $-159.27 Million | 4.127x | +162.92% |
| 2017-12-31 | $30.54 Million | $-200.29 Million | -6.559x | +49.73% |
| 2016-12-31 | $19.35 Million | $-252.54 Million | -13.049x | -183.72% |
| 2015-12-31 | $-6.93 Million | $-107.99 Million | 15.585x | +4448.32% |
| 2014-12-31 | $66.76 Million | $-23.93 Million | -0.358x | +1.51% |
| 2013-12-31 | $-42.38 Million | $15.42 Million | -0.364x | +81.67% |
| 2012-12-31 | $9.19 Million | $-18.25 Million | -1.986x | -- |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more